BiotechTube

iloprost

Pre-clinicalWithdrawn
0 watching 0 views this week💤 Quiet
20
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Persistent Pulmonary Hypertension

Conditions

Persistent Pulmonary Hypertension, Respiratory Distress Syndrome

Trial Timeline

May 1, 2006 → Oct 1, 2008

NCT ID
NCT00216931

About iloprost

iloprost is a pre-clinical stage product being developed by Bayer for Persistent Pulmonary Hypertension. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00216931. Target conditions include Persistent Pulmonary Hypertension, Respiratory Distress Syndrome.

Hype Score Breakdown

Clinical
5
Activity
2
Company
7
Novelty
2
Community
1

Clinical Trials (2)

NCT IDPhaseStatus
NCT01054105Pre-clinicalCompleted
NCT00216931Pre-clinicalWithdrawn

Competing Products

20 competing products in Persistent Pulmonary Hypertension

See all competitors
ProductCompanyStageHype Score
E7777 9 mcg/kgEisaiPhase 3
77
DE-105 ophthalmic solution + DE-105 ophthalmic solution + Placebo ophthalmic solutionSanten PharmaceuticalPhase 2
52
Phase IIb formulation + Putative phase III formulation + Slow dissolution variant 1 + Slow dissolution variant 2 + Test treatment EAstraZenecaPhase 1
33
AZD0837 + VKA INR 2-3AstraZenecaPhase 2
52
AZD0837 + AspirinAstraZenecaPhase 2
52
Montelukast to placebo + Placebo to montelukastMerckPre-clinical
23
Everolimus + Tamoxifen + Letrozole + Medroxyprogesterone AcetateNovartisPhase 2
52
Formoterol 12 mcg + Fluticasone propionate 100 mcg + Fluticasone propionate 250 mcg + Fluticasone propionate 500 mcg + PlaceboNovartisApproved
85
CertoparinNovartisPhase 3
77
Omalizumab + PlaceboNovartisPhase 3
77
RivastigmineNovartisApproved
85
QAW039 capsules once daily for 28 days + Placebo to QAW039 capsules once daily for 28 days + Fluticasone propionate inhaler twice daily for 28 daysNovartisPhase 2
52
Indacaterol + Placebo to IndacaterolNovartisPhase 2
52
Omalizumab + PlaceboNovartisApproved
85
placebo + iv sildenafilPfizerPhase 3
76
etanercept + placeboPfizerPhase 2
51
SildenafilPfizerPhase 2
51
irbesartan + placeboSanofiApproved
84
IV Remodulin + PlaceboUnited TherapeuticsPhase 2
49
Nexagon® (lufepirsen) High Dose Concentration + Nexagon® (lufepirsen) Low Dose Concentration + Vehicle + Open-label Nexagon® (lufepirsen)GlaukosPhase 2
49

Other Products from Bayer

TelmisartanApproved
82
Clotrimazole vaginal tablet + FluconazoleApproved
82
Levitra (Vardenafil, BAY38-9456)Approved
82
Avelox (Moxifloxacin, BAY12-8039) + Amoxicillin clavulanic acidApproved
82
Rivaroxaban 20 MG + WarfarinApproved
82